

David Laharie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4671325/publications.pdf>

Version: 2024-02-01

91
papers

5,288
citations

109264

35
h-index

85498

71
g-index

92
all docs

92
docs citations

92
times ranked

4293
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped. <i>Gastroenterology</i> , 2012, 142, 63-70.e5.	0.6	558
2	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1909-1915.	6.3	517
3	Infliximab Plus Azathioprine for Steroid-Dependent Crohn's Disease Patients: A Randomized Placebo-Controlled Trial. <i>Gastroenterology</i> , 2006, 130, 1054-1061.	0.6	362
4	Ineffectiveness of <i>Lactobacillus johnsonii</i> LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. <i>Gut</i> , 2006, 55, 842-847.	6.1	351
5	Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1343-1351.e1.	0.6	240
6	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1593-1601.e2.	2.4	168
7	A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. <i>American Journal of Gastroenterology</i> , 2010, 105, 2617-2625.	0.2	164
8	Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti-Tumor Necrosis Factor Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1048-1055.	2.4	158
9	Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. <i>Gut</i> , 2007, 56, 1404-1409.	6.1	157
10	Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 242-250.e2.	2.4	155
11	Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1425-1433.	0.9	149
12	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 310-321.	1.9	128
13	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	0.6	126
14	Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. <i>Gut</i> , 2018, 67, 237-243.	6.1	119
15	Serum calprotectin as a biomarker for Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e678-e683.	0.6	113
16	Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 998-1004.	1.9	92
17	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 485-493.	1.9	91
18	Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 714-721.	1.9	78

#	ARTICLE	IF	CITATIONS
19	Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 462-469.	1.9	78
20	Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 338-353.	1.9	78
21	Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 588-595.	1.9	73
22	Long-Term Outcome of Enterocutaneous Fistula in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Cohort Study from the GETAID. <i>American Journal of Gastroenterology</i> , 2014, 109, 1443-1449.	0.2	63
23	Association between enterohepatic <i>Helicobacter</i> species and Crohn's disease: a prospective cross-sectional study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 283-293.	1.9	62
24	Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 494-501.	2.4	62
25	Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1347-1352.	0.6	61
26	Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1039-1046.	1.9	54
27	Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1179-1185.	0.6	53
28	No Change in Determining Crohn's Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of the Rutgeerts Scoring System. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1643-1645.	2.4	53
29	Interobserver Variation Study of the Rutgeerts Score to Assess Endoscopic Recurrence after Surgery for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1001-1005.	0.6	50
30	Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 460-470.	1.9	49
31	Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: Results from a prospective study. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 69-76.	0.9	48
32	Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 487-493.	0.8	47
33	Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 40-53.	1.9	46
34	Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 905-913.	2.4	42
35	Predictors of response to infliximab in luminal Crohn's disease. <i>Gastroenterologie Clinique Et Biologique</i> , 2005, 29, 145-149.	0.9	40
36	Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn's Disease: A Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 222-227.	0.6	36

#	ARTICLE	IF	CITATIONS
37	Helicobacter pullorum Cytolethal Distending Toxin Targets Vinculin and Cortactin and Triggers Formation of Lamellipodia in Intestinal Epithelial Cells. <i>Journal of Infectious Diseases</i> , 2014, 209, 588-599.	1.9	33
38	Study of Helicobacter pullorum proinflammatory properties on human epithelial cells in vitro. <i>Gut</i> , 2009, 58, 629-635.	6.1	32
39	Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 982-987.	0.6	31
40	Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 852-860.	1.9	31
41	Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 713-720.e1.	2.4	31
42	Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn's Disease: A Prospective Cohort-Study in High-Risk Patients. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 47-52.	0.6	27
43	Demyelination in a patient receiving ustekinumab for refractory Crohn's disease: Figure 1. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1138-1139.	0.6	26
44	Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 312-319.	1.9	26
45	Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 944-951.	1.9	24
46	Towards therapeutic choices in ulcerative colitis. <i>Lancet</i> , The, 2017, 390, 98-99.	6.3	21
47	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 620-627.e1.	2.4	21
48	864 Close Monitoring of CRP and Fecal Calprotectin is Able to Predict Clinical Relapse in Patients With Crohn's Disease in Remission After Infliximab Withdrawal. a Sub-Analysis of the Stori Study. <i>Gastroenterology</i> , 2012, 142, S-149.	0.6	20
49	Remission of protein-losing enteropathy after nodal lymphoma treatment in a patient with primary intestinal lymphangiectasia. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1417-1419.	0.8	19
50	Recommendations Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED). <i>Endoscopy</i> , 2013, 45, 936-943.	1.0	17
51	The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1240-1248.	1.9	16
52	Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study. <i>Gut</i> , 2021, 70, 1450-1457.	6.1	16
53	Postoperative Crohn's Disease Recurrence: Time to Adapt Endoscopic Recurrence Scores to the Leading Surgical Techniques. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1201-1204.	2.4	13
54	Impact of Preexisting Inflammatory Bowel Disease on the Outcome of Liver Transplantation for Primary Sclerosing Cholangitis. <i>Liver Transplantation</i> , 2020, 26, 1477-1491.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 896-903.	0.6	12
56	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1180-1188.e4.	2.4	12
57	921 Long Term Follow-Up of a Cohort of Steroid-Dependent Crohn's Disease Patients Included in a Randomized Trial Evaluating Short Term Infliximab Combined with Azathioprine. <i>Gastroenterology</i> , 2008, 134, A-134.	0.6	11
58	Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2074-2082.	2.4	11
59	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 713-722.	1.9	10
60	Assessment of sexual dysfunction in patients with perianal Crohn's disease. <i>Colorectal Disease</i> , 2021, 23, 114-122.	0.7	9
61	Determinants of IBD-related disability: a cross-sectional survey from the GETAID. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1098-1107.	1.9	9
62	Oncological outcomes of IBD-associated versus sporadic colorectal cancer in modern era: a matched case-control study. <i>International Journal of Colorectal Disease</i> , 2018, 33, 963-966.	1.0	8
63	Altered sleep quality is associated with Crohn's disease activity: an actimetry study. <i>Sleep and Breathing</i> , 2020, 24, 971-977.	0.9	8
64	Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1354-1355.e2.	2.4	8
65	Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1454-1462.	0.6	8
66	Surgery for Crohn's disease during pregnancy: A nationwide survey. <i>United European Gastroenterology Journal</i> , 2020, 8, 736-740.	1.6	7
67	Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 400-409.	1.9	6
68	Compliance with Gluten Free Diet Is Associated with Better Quality of Life in Celiac Disease. <i>Nutrients</i> , 2022, 14, 1210.	1.7	5
69	Severe endoscopic lesions are not associated with more infliximab fecal loss in acute severe ulcerative colitis. <i>Digestive and Liver Disease</i> , 2018, 50, 1100-1103.	0.4	4
70	Letter: should we intensify infliximab in acute severe ulcerative colitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 186-187.	1.9	4
71	Endoscopic and histologic response to cyclosporine in ulcerative colitis and their impact on disease outcome: A cohort study. <i>Digestive and Liver Disease</i> , 2016, 48, 734-739.	0.4	3
72	Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAID. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1000-1008.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 689-690.	1.9	2
74	Anti- α TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 831-838.	1.9	2
75	Male gender is associated with informal caregiver burden in patients with chronic intestinal failure treated with home parenteral nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 1593-1601.	1.3	2
76	Tu1137 Hemophagocytic Syndrome During Inflammatory Bowel Disease (IBD): A Serious and Unfamiliar Complication of Immunosuppressive Therapy. <i>Gastroenterology</i> , 2013, 144, S-771-S-772.	0.6	1
77	Letter: which patient profile for tacrolimus in ulcerative colitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1242-1243.	1.9	1
78	Concise Commentary: Spaced Out—Reducing the Relapse Risk in IBD Patients by Lengthening Dosing Intervals of Anti-TNFs. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2044-2045.	1.1	1
79	P472 Changes in colectomy for Ulcerative Colitis during the last two decades: an in-depth retrospective analysis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i444-i444.	0.6	1
80	Editorial: don't forget basic performance measures in the endoscopic assessment of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 129-130.	1.9	1
81	Editorial: is enteral nutrition back in acute severe ulcerative colitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 745-746.	1.9	1
82	Letter: mucosal healing in ulcerative colitis — higher relevance than in Crohn's disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 208-208.	1.9	0
83	Reply. <i>Gastroenterology</i> , 2016, 150, 1239.	0.6	0
84	Medical Treatment of Inflammatory Bowel Disease. , 2017, , 229-239.		0
85	Controverse. <i>Colon and Rectum</i> , 2017, 11, 108-116.	0.0	0
86	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1214-1215.	2.4	0
87	Concise Commentary: Second Line Is Not Second Best—Continuing Validity of the Oxford Criteria in the Management of Acute Severe Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 581-582.	1.1	0
88	DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i131-i132.	0.6	0
89	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
90	Editorial: biologics in the therapy of Crohn's disease—the fog clears. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1214-1215.	1.9	0

#	ARTICLE	IF	CITATIONS
91	Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 857-858.	1.9	0